Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study

Drug and Alcohol Dependence

Volumn 105, Issue 3, 2009, Pages 256-258

  Ray, Lara A ^a   Oslin, David W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

African American; COMBINE Study; Naltrexone; Pharmacogenetics

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ADULT; AFRICAN AMERICAN; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOTHERAPY; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; ALCOHOL DETERRENTS; ALCOHOLISM; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; TAURINE; TREATMENT OUTCOME;

EID: 70349887741     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.07.006     Document Type: Article

References (23)

1. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., and Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry 156 (1999) 1758-1764
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., and Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE Study: a randomized controlled trial. JAMA 295 (2006) 2003-2017
3. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., and Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65 (2008) 135-144
4. Arias A., Feinn R., and Kranzler H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 83 (2006) 262-268
5. Chick J., Anton R., Checinski K., Croop R., Drummond D.C., Farmer R., Labriola D., Marshall J., Moncrieff J., Morgan M.Y., Peters T., and Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 35 (2000) 587-593
6. Cisler R.A., and Zweben A. Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol Clin. Exp. Res. 23 (1999) 263-271
7. Cohen J. A power primer. Psychol. Bull. 112 (1992) 155-159
8. COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE Study): a pilot feasibility study. Alcohol Clin. Exp. Res. 27 (2003) 1123-1131
9. COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin. Exp. Res. 27 (2003) 1107-1122
10. Litten R.Z., Allen J., and Fertig J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin. Exp. Res. 20 (1996) 859-876
11. Miller W.R., and Del Boca F.K. Measurement of drinking behavior using the Form 90 family of instruments. J. Stud. Alcohol. Suppl. 12 (1994) 112-118
12. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I., Brown R.A., Gordon A., Abrams D.B., Niaura R.S., and Asher M.K. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin. Exp. Res. 25 (2001) 1634-1647
13. Morris P.L., Hopwood M., Whelan G., Gardiner J., and Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96 (2001) 1565-1573
14. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 49 (1992) 881-887
15. Oroszi G., Anton R.F., O'Malley S., Swift R., Pettinati H., Couper D., Yuan Q., and Goldman D. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin. Exp. Res. 33 (2009) 383-393
16. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., and O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28 (2003) 1546-1552
17. Ray L.A., and Hutchison K.E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin. Exp. Res. 28 (2004) 1789-1795
18. Ray L.A., and Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64 (2007) 1069-1077
19. SAS Institute Inc. The SAS System for Windows (2003), SAS Institute Inc., Cary, NC
20. Srisurapanont M., and Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. (2005) CD001867
21. Tate S.K., and Goldstein D.B. Will tomorrow's medicines work for everyone?. Nat. Genet. 36 (2004) S34-S42
22. Tonigan J.S., Miller W.R., and Brown J.M. The reliability of Form 90: an instrument for assessing alcohol treatment outcome. J. Stud. Alcohol 58 (1997) 358-364
23. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49 (1992) 876-880